FDA Breakthrough Status for Daridorexant Opens Pediatric Insomnia Path

The FDA has granted Breakthrough Therapy Designation to daridorexant for insomnia disorder in patients aged 10 to under 18 years — a population that currently has no FDA-approved pharmacological treatment for the condition.

The designation covers Idorsia's dual orexin receptor antagonist (DORA), a drug class that selectively reduces wake drive rather than broadly inhibiting brain activity. It entitles the Swiss developer to intensive FDA guidance and closer collaboration intended to expedite pediatric development.

"This Breakthrough Therapy Designation underscores both the significant unmet medical need faced by children and adolescents living with insomnia disorder and the encouraging clinical evidence generated with daridorexant to date," said Amer Joseph, MD, Idorsia's chief medical officer and head of global clinical development. "Daridorexant was specifically designed with an optimized pharmacokinetic and tolerability profile, allowing it to be largely cleared by the next morning and avoiding accumulation with repeated dosing."

What data support the designation?

The FDA's decision rests on a multicenter, randomized, double-blind, placebo-controlled phase 2 dose-finding study. The trial enrolled 165 children and adolescents and evaluated doses of 10, 25 and 50 mg of daridorexant against placebo over two weeks.

The primary endpoint — objective total sleep time measured from baseline on day 1 — improved in a statistically significant, dose-dependent manner.

The headline figures come from the 50 mg dose:

• A single dose increased total sleep time by 50 minutes across the overall study population.
• In children and adolescents with neurodevelopmental disorders, the gain reached 64 minutes.

The study also addressed the safety questions that matter most in pediatric prescribing. Investigators recorded no adverse events denoting drug abuse during treatment and no indication of withdrawal symptoms upon discontinuation — findings relevant to any sedative-class compound used in children.

Idorsia funded the trial; the designation itself is a regulatory judgment on the evidence, not an approval.

Why the pediatric gap matters

Pediatric insomnia affects approximately 8% to 12% of children and adolescents, according to figures cited with the announcement. The burden falls disproportionately on those with neurodevelopmental disorders, including autism spectrum disorder and attention-deficit/hyperactivity disorder.

Until now, that population has had no approved drug option. Clinicians managing these patients have had to rely on behavioral interventions or off-label use of adult insomnia medications, an approach with a thin pediatric evidence base.

What happens next?

Idorsia is consolidating supportive comments from global health authorities on the protocol for its pediatric phase 3 clinical development program. The company expects to initiate that program in the second half of next year.

For R&D managers tracking the sleep therapeutics portfolio, the timeline is concrete: a phase 3 start in roughly 12 months, an expedited FDA pathway already in hand, and a phase 2 dataset that separates measured same-night efficacy from the longer-term safety questions a pivotal pediatric program will need to answer.